What Should Investors Know About Pfizer (PFE) Stock?

Pharma company Pfizer posted a -1.69% performance today, while the S&P 500 returned 0.62%.

20 analysts are following Pfizer and have set target prices ranging from $40.0 to $75.0 per share. On average, they have given the company a rating of buy. At today's prices, PFE is trading -21.85% away from its average analyst target price of $52.52 per share.

Over the last year, PFE shares have gone down by -9.53%, which represents a difference of -0.3% when compared to the S&P 500. The stock's 52 week high is $54.46 per share and its 52 week low is $40.72. With average free cash flows of $18,227,400,000 that have been growing at an average rate of 26.78% over the last four years, Pfizer declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations (k) Capital Expenditures (k) Free Cash Flow (k) YoY Growth
2022-12-31 $29,267,000 $3,236,000 $26,031,000 -12.85%
2021-12-31 $32,580,000 $2,711,000 $29,869,000 157.23%
2020-12-31 $14,403,000 $2,791,000 $11,612,000 16.19%
2019-12-31 $12,588,000 $2,594,000 $9,994,000 -26.68%
2018-12-31 $15,827,000 $2,196,000 $13,631,000 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.